Humatrope, Nutropinaq(somatropin)
Genotropin, Humatrope, Norditropin, Nutropin, NutropinAq, Omnitrope, Saizen, Serostim, Zomacton (somatropin) is a protein pharmaceutical. Somatropin was first approved as Humatrope on 1986-10-16. It is used to treat cachexia, dwarfism, heart failure, noonan syndrome, and prader-willi syndrome amongst others in the USA. It has been approved in Europe to treat growth, pituitary dwarfism, prader-willi syndrome, and turner syndrome. The pharmaceutical is active against growth hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| nervous system diseases | D009422 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
| skin and connective tissue diseases | D017437 |
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
| signs and symptoms pathological conditions | D013568 |
| physiological phenomena | D010829 |
Trade Name
FDA
EMA
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Serostim, Zomacton (discontinued: Accretropin, Zorbtive/serostim)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Somatropin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Nutropin AQ | somatropin | Genentech, Inc. | N-20522 RX | 2008-01-03 | 3 products |
| Saizen | somatropin | EMD Serono | N-19764 RX | 1996-10-08 | 2 products |
| Serostim | somatropin | EMD Serono | N-20604 RX | 1996-08-23 | 3 products |
| Humatrope | somatropin | Eli Lilly | N-19640 RX | 1986-10-16 | 4 products |
| Zomacton | somatropin | Ferring Pharmaceuticals Inc. | N-19774 RX | 1995-05-25 | 3 products |
| Norditropin | somatropin | Novo Nordisk Inc. | N-21148 RX | 2010-03-01 | 4 products |
| Genotropin | somatropin | Pharmacia & Upjohn Company LLC | N-20280 RX | 1995-08-24 | 12 products |
| Omnitrope | somatropin | Sandoz Inc. | N-21426 RX | 2006-05-30 | 3 products |
Show 10 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| genotropin | Biologic Licensing Application | 2020-04-14 |
| humatrope | Biologic Licensing Application | 2021-02-02 |
| norditropin | Biologic Licensing Application | 2020-03-09 |
| nutropin aq nuspin 10 nutropin aq nuspin 20 nutropin aq nuspin 5 | Biologic Licensing Application | 2020-06-29 |
| omnitrope | Biologic Licensing Application | 2019-06-18 |
| saizen saizenprep | Biologic Licensing Application | 2020-04-07 |
| serostim | Biologic Licensing Application | 2020-05-22 |
| zomacton | Biologic Licensing Application | 2020-07-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cachexia | HP_0004326 | D002100 | R64 |
| dwarfism | — | D004392 | E34.31 |
| heart failure | EFO_0003144 | D006333 | I50 |
| noonan syndrome | Orphanet_648 | D009634 | Q87.19 |
| prader-willi syndrome | Orphanet_739 | D011218 | Q87.11 |
| turner syndrome | Orphanet_881 | D014424 | Q96 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
somatropin, Norditropin, Novo Nordisk Inc. | |||
| 2114-05-31 | Orphan excl. | ||
somatropin, Humatrope, Eli Lilly and Company | |||
| 2113-11-01 | Orphan excl. | ||
somatropin, Genotropin, Pharmacia & Upjohn Company LLC | |||
| 2108-07-25 | Orphan excl. | ||
somatropin, Nutropin, Genentech, Inc. | |||
| 2103-12-30 | Orphan excl. | ||
somatropin, Serostim, EMD Serono, Inc. | |||
| 2103-08-23 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2941 | Injection, somatropin, 1 mg |
Clinical
Clinical Trials
427 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | 9 | 22 | 40 | 25 | 35 | 130 |
| Turner syndrome | D014424 | Orphanet_881 | Q96 | 1 | 5 | 7 | 7 | 10 | 30 |
| Healthy volunteers/patients | — | 12 | — | — | 3 | 3 | 18 | ||
| Inborn genetic diseases | D030342 | EFO_0000508 | 1 | — | 5 | 3 | 8 | 17 | |
| Infertility | D007246 | EFO_0000545 | 2 | 4 | 2 | 4 | 2 | 12 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 3 | 3 | 2 | 4 | 12 |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | 1 | — | 4 | 2 | 3 | 10 |
| Chronic renal insufficiency | D051436 | N18 | 1 | 1 | 2 | 4 | 2 | 10 | |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | 3 | 2 | 3 | 3 | 10 |
| Pituitary dwarfism | D004393 | EFO_1001109 | E23.0 | — | 1 | 2 | 3 | 3 | 9 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Growth disorders | D006130 | 4 | 1 | 8 | — | 4 | 17 | ||
| Pituitary diseases | D010900 | E23.7 | — | — | 7 | — | 1 | 8 | |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | 8 | — | — | 8 |
| Noonan syndrome | D009634 | Orphanet_648 | Q87.19 | — | — | 4 | — | 3 | 7 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | 3 | 2 | — | 2 | 7 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 5 | 2 | — | — | 7 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 3 | 1 | — | 1 | 4 |
| Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | 1 | — | — | 3 | |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | 1 | 1 | — | 1 | 3 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | 3 | — | — | 3 |
Show 28 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aging | D000375 | GO_0007568 | R41.81 | 1 | 3 | — | — | 1 | 4 |
| Insulin resistance | D007333 | EFO_0002614 | 2 | 1 | — | — | 2 | 4 | |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 2 | 1 | — | — | — | 3 |
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | 1 | 1 | — | — | 1 | 2 | |
| Chronic kidney disease-mineral and bone disorder | D012080 | EFO_1001152 | N25.0 | — | 1 | — | — | — | 1 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 1 | — | — | — | 1 |
| Gonadal dysgenesis | D006059 | — | 1 | — | — | — | 1 | ||
| Rupture | D012421 | — | 1 | — | — | — | 1 | ||
| Body weight changes | D001836 | 1 | 1 | — | — | — | 1 | ||
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Facioscapulohumeral muscular dystrophy | D020391 | EFO_0000491 | G71.02 | 1 | — | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | — | — | — | — | 1 |
| Hypophosphatemic rickets | D063730 | E83.31 | 1 | — | — | — | — | 1 | |
| Post-concussion syndrome | D038223 | EFO_1001827 | F07.81 | 1 | — | — | — | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 1 | — | — | — | — | 1 |
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acromegaly | D000172 | — | — | — | — | 2 | 2 | ||
| Fatty liver | D005234 | — | — | — | — | 1 | 1 | ||
| Metabolism | D008660 | GO_0008152 | — | — | — | — | 1 | 1 | |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Ketosis | D007662 | HP_0002919 | R82.4 | — | — | — | — | 1 | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 1 | 1 |
| Pituitary neoplasms | D010911 | — | — | — | — | 1 | 1 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Werner syndrome | D014898 | Orphanet_902 | E34.8 | — | — | — | — | 1 | 1 |
| Chromosome aberrations | D002869 | Orphanet_68335 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SOMATROPIN |
| INN | somatropin |
| Description | Accretropin, Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive/Serostim, NutropinAq (somatropin) is a protein pharmaceutical. Somatropin was first approved as Accretropin on 2001-02-15. It is used to treat cachexia, dwarfism, heart failure, noonan syndrome, and prader-willi syndrome amongst others in the USA. It has been approved in Europe to treat pituitary dwarfism, prader-willi syndrome, and turner syndrome. The pharmaceutical is active against growth hormone receptor. |
| Classification | Protein |
| Drug class | tricyclic compounds; growth hormone derivatives; atropine derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201621 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | NQX9KB6PCL (ChemIDplus, GSRS) |
Target
Agency Approved
GHR
GHR
Alternate
No data
Variants
Clinical Variant
No data
Financial
Genotropin - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,441 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,140 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more